ABOUT CYTOVANCE BIOLOGICS
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its state-of-the-art Oklahoma City facilities.
Our Mission Statement
Cytovance® Biologics' mission is to become a valuable partner to our clients by providing an integral pathway in converting today's novel protein discoveries into future lifesaving therapies and diagnostics. Cytovance® is your partner in the biopharmaceutical contract manufacturing of therapeutic proteins and antibodies from mammalian cell culture and microbial fermentation.
At Cytovance®, we provide unparalleled support to biopharmaceutical companies to move new, safe medicines from the lab bench to those who need them most. We’re committed to a healthier world. Cytovance® offers a comprehensive range of development and cGMP manufacturing services, including:
When Working Cell Banks Won't Work
Cells grew in the lab, but wouldn't grow in an outsourced working cell bank. Here's how a contract manufacturer turned around the repeated failure of a client's master cell bank-to-working cell bank transfer.
Development Of A Modified Purification Process For A Monoclonal Antibody Therapeutic-Yield Improvement
A Mab product had been manufactured at the 2,000L scale and production at the 10,000L cGMP manufacturing scale was planned. Read how they improved yield of Mab product from bulk harvest by 1.8 fold by simplifying the downstream process in addition to eliminating the use of resins that were difficult to pack and resulted in declining yields with short life cycles.
Current Perspectives On Biosimilars
Biosimilars typically have a shorter timeline for approval and can be developed at 20 percent the cost of the innovator. This paper covers the quality management system required for traceable, trackable data.
200-Fold Scale-Up Of A Fed-Batch Bioreactor Process
The client had performed preliminary bioreactor runs at the 0.5 scale with the CHO cell line and required a rapid 200 fold scale-up to the 100L bioreactor level with minimal process development.
Development Of A Drop-In Purification Step For Removal Of Aggregates From An Antibody Therapeutic
A client was engaged in large scale cGMP manufacturing operations at a major CMO and their product contained high levels of aggregate following an affinity capture step. Subsequent chromatography steps reduced the aggregate level to acceptable levels but product losses were encountered in elution buffers, and stat in-process assays. Read how they were able to reduce aggregate level and simplify the downstream purification process.
Application Of DSD To The icIEF Assay Development Of Antibodies And Therapeutic Proteins
Here we describe a design of experiments approach using a definitive screening design model to optimize the icIEF development of a glycosylated protein transferrin and an IgG1 monoclonal antibody.
CHO Cell Line Development Toolbox For Productivity, Stability
The selection of good synthetic genes for monoclonal antibody expression in CHO-S cells is labor intensive, time consuming, and costly. This poster illustrates a way to simplify the process.
Comparison Of Different Methods Of Clarification Of CHO Cells
Clarification methods for commercial biotherapeutic manufacturing require simplicity and scalability. This study evaluates alluvial filtration, depth filtration and flocculant filtration process for clarification.